Stocktoria
Arcus Biosciences, Inc. RCUS
Arcus Biosciences, Inc. (RCUS) earns a Piotroski F-score of 0/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $247.0M at a -142.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-04 | LifeSci Capital | Outperform (init) |
| 2026-05-11 | Morgan Stanley | Equal-Weight (main) |
| 2026-05-07 | Goldman Sachs | Buy (main) |
| 2026-04-02 | Wedbush | Outperform (main) |
| 2026-03-05 | Citigroup | Buy (main) |
| 2026-03-02 | Leerink Partners | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.681 |
| Retained earnings / assets | -1.304 |
| EBIT / assets | -0.339 |
| Equity / liabilities | 1.242 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RCUS | Arcus Biosciences, Inc. | 0/9 | -0.75 | — | -4.3% |
| KROS | Keros Therapeutics, Inc. | 6/9 | 11.55 | 2.5 | — |
| SDGR | Schrodinger, Inc. | 4/9 | -0.33 | — | +23.3% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
| ANAB | ANAPTYSBIO, INC | 5/9 | -0.3 | — | +157% |
| ARVN | ARVINAS, INC. | 4/9 | -1.73 | — | -0.3% |
| LFVN | Lifevantage Corp | 6/9 | -0.45 | 8.5 | +14.2% |
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
FAQ
Is RCUS financially healthy?
Arcus Biosciences, Inc.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RCUS pay a dividend?
No, Arcus Biosciences, Inc. does not currently pay a dividend.
How profitable is RCUS?
In FY2025, Arcus Biosciences, Inc. had a net margin of -142.9% and a return on equity of -55.9%.
What is the analyst price target for RCUS?
The average Wall-Street price target for Arcus Biosciences, Inc. is $35.75, about 23.4% above the recent price, from 12 analysts (consensus: strong buy).
Is RCUS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Arcus Biosciences, Inc.: a Piotroski F-score of 0/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.